Inside the KLOW Peptide Stack: The Four Peptides
In plain English
The KLOW stack puts four peptides with very different clearance rates into one vial. BPC-157 — the largest component at 1419 Da — has a formal elimination half-life of under approximately 30 minutes from the published rat/dog pharmacokinetic study. The two tripeptides KPV (342 Da) and GHK-Cu (402 Da) are smaller still and clear even faster. TB-500, the synthetic heptapeptide fragment, has no formal published half-life study after subcutaneous injection.
The consequence: in a co-dissolved 80 mg vial, all four components are present at the moment of injection, but they will not all be at meaningful plasma concentrations at the same time. The shortest-lived components clear first, and the four-arm coverage assumed in the blend rationale does not occur as a simultaneous event.
This page is the pharmacokinetics reference for the KLOW stack — the half-life ledger and delivery-route data, one component at a time.
Inside the KLOW stack — component half-life ledger
The following pharmacokinetic data is drawn from published per-component studies. No combined PK study of the KLOW blend exists.
KPV (Lys-Pro-Val, MW 342.44 Da) Reported half-life: no formal IV half-life study published. As a tripeptide of 342 Da, plasma peptidase clearance is expected to be rapid — consistent with the class. Primary relevant route: PepT1 (SLC15A1)-mediated uptake into gut epithelial and immune cells (Km ~160 micromolar), making this component's activity localized to the gut mucosa rather than a broad systemic signal [3]. Route studied in vivo: oral in mice; cell-culture medium in vitro.
GHK-Cu (MW 402.92 Da) Reported half-life: a rat HPLC study showed rapid plasma degradation of free GHK to HK (histidyl-lysine) after IV administration; detection limit 50 ng/mL GHK, 15 ng/mL HK [9]. No validated human half-life. The copper(II) ion has its own metabolic fate separate from the peptide scaffold. Routes studied: intravenous (PK study), topical (skin and wound studies [4]), cell culture.
BPC-157 (MW 1419.53 Da) Reported half-life: elimination half-life under approximately 30 minutes in rats and beagle dogs; intramuscular bioavailability approximately 14-19% in rats, approximately 45-51% in dogs; excretion via urine and bile; linear pharmacokinetics [8]. This is the most formally characterized component. Routes studied: intravenous, intramuscular, intraperitoneal, subcutaneous, oral/targeted.
TB-500 (Ac-LKKTETQ, MW approximately 889 Da) Reported half-life: no formal published pharmacokinetic half-life study after subcutaneous injection of the TB-500 fragment specifically. An equine doping-control analytical method confirmed the compound in horse plasma (LOD 0.02 ng/mL) and urine (LOD 0.01 ng/mL) [10], establishing detection methodology rather than clearance kinetics. Full-length native thymosin beta-4 (43 aa, ~4.9 kDa) has different pharmacokinetics from the short fragment. Routes studied: topical (thymosin beta-4 wound studies [1]), IV (cardiac trials [13]), subcutaneous (animal models).
Delivery routes in the component literature
The component literature covers multiple routes. These are research contexts only — routes used in published studies — not protocol recommendations.
Subcutaneous injection appears in BPC-157 and thymosin beta-4 animal models and is the most common handling route for research-peptide co-formulations. Intraperitoneal injection was the primary route in most BPC-157 rodent studies; the 10 μg/kg IP dose is the anchor for the tendon-healing finding [2]. Intravenous administration was used in the BPC-157 human safety pilot [6], the GHK-Cu rat PK study [9], and the thymosin beta-4 cardiac trial [13]. Topical application is relevant for GHK-Cu (skin and wound studies [4]) and thymosin beta-4 wound studies [1], including the RGN-259 ophthalmic formulation [12]. Oral/targeted delivery was used for KPV in mouse colitis studies [3] and PepT1-targeted nanoparticle systems [14].
For the KLOW co-formulation, subcutaneous injection is the most commonly cited laboratory handling route across community sources. No route comparison study exists for the blend.
The pharmacokinetic mismatch — honest accounting
The PK mismatch is not a marketing concern — it is a physical consequence of combining four peptides with molecular weights from 342 Da to 1419 Da and fundamentally different metabolic fates.
BPC-157 at 1419 Da clears in under approximately 30 minutes [8]. KPV at 342 Da and GHK-Cu at 402 Da are smaller and degraded by plasma peptidases even more rapidly [9][3]. TB-500 at ~889 Da as an N-acetylated heptapeptide sits in between — its clearance is uncharacterized for the fragment but the peptide class suggests it will not persist substantially longer than BPC-157.
In a single co-dissolved 80 mg vial: at the moment of reconstitution all four are present. After injection, the fastest-clearing components begin disappearing first. By the time any late-phase tissue-delivery or depot effect is ongoing for one component, the shortest-lived components are already largely gone from the systemic compartment.
The blend rationale — four complementary mechanisms addressing the same cascade simultaneously — is weakened by this reality. Whether the brief window of co-presence is sufficient for a synergistic interaction is unanswered, and 'synergy' in any case has not been tested. This is the central honest gap this reference is built around.
The KLOW references page has the full citations behind these PK facts.